Company intelligence / Profile preview

IAMA Conseils

Genoa, Liguria, Italyiamatherapeutics.com ↗

Ownership: Private
Development stage: Phase 1

Overview

IAMA Therapeutics has completed a Phase 1 trial of its lead NKCC1 inhibitor IAMA-6 in healthy volunteers, demonstrating safety, tolerability, and target engagement, and is preparing to advance into Phase 2 studies in neurodevelopmental and epilepsy indications.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

IAMA-6

Phase 1

Indications: Central nervous system disorders, Neurological disorders

Partnerships

Evotec (multi‑phase strategic provider agreement for IND‑enabling, manufacturing, and Phase 1 clinical trial services for IAMA‑6)

Beyond the preview

Go deeper on IAMA Conseils.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IAMA Conseils.

Explore the full profile